SB Investment Advisers (UK) Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GETR
Getaround, Inc.
GETR
|
+$165M |
| 2 |
Ginkgo Bioworks
DNA
|
+$56.2M |
| 3 |
Full Truck Alliance
YMM
|
+$30.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Coupang
CPNG
|
+$618M |
| 2 |
DoorDash
DASH
|
+$221M |
| 3 |
ZY
Zymergen Inc. Common Stock
ZY
|
+$74M |
| 4 |
Vir Biotechnology
VIR
|
+$44.8M |
| 5 |
Roivant Sciences
ROIV
|
+$24.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 61.26% |
| 2 | Technology | 19.64% |
| 3 | Healthcare | 14.43% |
| 4 | Real Estate | 3.54% |
| 5 | Materials | 0.53% |
Similar funds
SB Investment Advisers (UK)'s Q4 2022 Portfolio in Review
As of Q4 2022, SB Investment Advisers (UK) held 15 positions worth $12B, down 8.3% from $13.1B the previous quarter. Its ten largest holdings account for 99% of the portfolio.
SB Investment Advisers (UK) withdrew a net $730M in Q4 2022, closing 1 position and reducing 4 holdings. Its most notable exit was Zymergen Inc. Common Stock, an estimated $74M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 61% of assets, down from 69% a quarter earlier, followed by Technology and Healthcare.
Against the trend, SB Investment Advisers (UK) opened a new position in Getaround, Inc. worth $14M.
- SB Investment Advisers (UK)'s largest Q4 2022 buy was Getaround, Inc.: 21,516,384 shares worth $14M.
- SB Investment Advisers (UK) added most to Full Truck Alliance in Q4 2022, an estimated $30.2M increase.
- SB Investment Advisers (UK)'s biggest Q4 2022 reduction was Coupang, cutting an estimated $618M.
- SB Investment Advisers (UK) fully exited Zymergen Inc. Common Stock in Q4 2022, selling an estimated $74M.
- SB Investment Advisers (UK)'s ten largest holdings make up 99% of its $12B portfolio in Q4 2022.
- SB Investment Advisers (UK) opened 2 new positions and closed 1 in Q4 2022.
- SB Investment Advisers (UK)'s portfolio value fell 8.3% quarter-over-quarter to $12B.
Based on SB Investment Advisers (UK)'s 13F filing for Q4 2022, filed 14 Feb 2023.